Google Search

Monday, July 13, 2009

USA: Postdoctoral Position in Protein / Antibody Engineering for the Therapy of Autoimmunity (85), University of Texas

Protein/Antibody Engineering for the Therapy of Autoimmunity (85)

Postdoctoral positions are available in the laboratory of Prof. E. Sally Ward at UT Southwestern Medical Center at Dallas. Projects will include the use of state-of-the-art approaches to generate novel antibody-based therapeutics for autoimmunity and cancer. The work will involve the engineering of antibody-Fc receptor interactions and the use of new transgenic mouse models. These studies are of considerable relevance to the rapidly expanding use of antibodies as diagnostics and therapeutics in the biopharma industry. The projects are supported by institutions such as the National Institutes of Health, the National Multiple Sclerosis Society and the biopharma industry.

In collaboration with Prof. R.J. Ober, the laboratory provides a unique inter- and multi-disciplinary environment. Students have the opportunity to work on challenging technological problems in the framework of a laboratory that is devoted to the study of questions of fundamental biological relevance.

For more information on the research carried out in the laboratory see www4.utsouthwestern.edu/wardlab, or consult publications such as Proc. Natl. Acad. Sci. USA, in press, 2009; Proc. Natl. Acad. Sci. USA, 103, 18709-18714, 2006; Nature Biotechnol., 23, 1283-1288, 2005; J. Mol. Biol., 345, 1071-1081, 2005; Proc. Natl. Acad. Sci. USA, 101, 11076-11081, 2004;Nature Biotechnol., 15, 637-640, 1997; Nature, 341, 544-546, 1989.

Highly motivated applicants with a Ph.D. in any biological area, biotechnology or chemistry will be considered, but preference will be given to those with relevant research experience.

For inquiries please send materials (full resume, statement of interest, transcripts and names/contact information for three references) to wardlab[ at ]utsouthwestern.edu.

UT Southwestern is an Equal Opportunity, Affirmative Action Employer.

No comments: